What SS31 Does in Your Cells

SS31 is a short peptide—a chain of four amino acids—that crosses into mitochondria and appears to reduce harmful oxidative stress in those organelles. Unlike many compounds that work broadly across the cell, SS31 targets a specific location: the inner mitochondrial membrane, where it may stabilize cardiolipin, a lipid that helps the electron transport chain function. The mechanism is distinct from general antioxidants; instead of neutralizing free radicals everywhere, SS31 seems to prevent the formation of damaging reactive oxygen species at the point where energy is being made.

The peptide was originally developed by researchers at the National Institutes of Health and has been studied primarily in animal models and a small number of human trials. Most evidence comes from laboratory and animal studies, with human data still limited. The research suggests SS31 may be relevant to conditions involving mitochondrial dysfunction—heart disease, neurodegenerative disease, and aging-related decline—but the translation from animal work to proven human benefit remains incomplete.

Key Takeaways

  • SS31 is a four-amino-acid peptide that works specifically inside mitochondria, not throughout the whole cell like typical antioxidants.
  • Most evidence comes from animal studies and cell cultures; human trial data is limited to a handful of small studies.
  • Research has focused on heart disease, stroke recovery, and neurodegenerative conditions, but no large-scale human trials have confirmed benefit in any disease yet.
  • SS31 is not currently approved by the FDA for any medical use and is not available as a commercial supplement in the United States.
  • The distinction between what animal studies show and what human studies show is critical—animal models often do not translate to the same effects in people.

What Animal Studies and Early Human Research Show

In rodent models of heart attack, SS31 reduced infarct size and improved cardiac function when given around the time of the injury. Similar protective effects appeared in models of stroke, Parkinson's disease, and age-related muscle decline. These studies consistently showed that the peptide reduced markers of oxidative stress in mitochondria and preserved the function of the electron transport chain.

A small human trial published in 2018 examined SS31 in acute myocardial infarction (heart attack) patients. The study was short-term and involved a limited number of participants, but suggested the peptide was tolerated and showed some signal of benefit on heart function measures. However, this was not a large randomized controlled trial, and the sample size was too small to draw firm conclusions about clinical benefit. No large human trials have been completed since, and no regulatory approval has followed.

Research in neurodegenerative disease models—particularly Parkinson's and Alzheimer's—has shown promise in preserving neuronal function and reducing cell death markers. Again, these are animal and cell-based studies. Translation to human disease remains speculative, and no human trials in neurodegeneration have been published.

The Gap Between Animal Models and Human Evidence

Animal studies are valuable for understanding mechanism and identifying candidates for human testing, but they frequently do not predict human outcomes. A compound that reduces infarct size in a mouse heart attack model may not reduce mortality or disability in human patients. The controlled conditions of animal research—precise dosing, timing, genetics, and absence of comorbidities—rarely match the complexity of human disease.

SS31 illustrates this gap clearly. The animal evidence is encouraging and mechanistically sound, but the human evidence is sparse. One small trial in heart attack patients is not enough to establish that SS31 prevents death, reduces hospital readmission, or improves long-term quality of life. Until larger, well-designed human trials are completed and published, claims about clinical benefit remain preliminary.

Current Availability and Regulatory Status

SS31 is not approved by the FDA for any medical indication. It is not available as a dietary supplement in the United States. Some research institutions and clinical trial sites may have access to the peptide for investigational use, but it is not sold commercially and cannot be legally marketed as a treatment or supplement.

A few clinical trials involving SS31 have been registered or completed, but most remain in early phases or have not yet published results. If you encounter SS31 being sold online or marketed as a treatment, it is either mislabeled, unregulated, or both. The peptide's status as a research compound means that quality, purity, and safety of any product claiming to contain it cannot be verified outside of clinical trial settings.

How SS31 Fits Into NAD Pathway Research

SS31 is grouped with NAD pathway compounds because mitochondrial health and NAD metabolism are interconnected. NAD (nicotinamide adenine dinucleotide) is a coenzyme central to energy production and cellular repair. When mitochondria are damaged or dysfunctional—which SS31 is designed to prevent—NAD-dependent processes like sirtuin set up and DNA repair become impaired. By protecting mitochondrial structure and reducing oxidative stress, SS31 may indirectly support NAD-dependent signaling.

However, SS31 does not directly increase NAD levels or set up sirtuins the way some other compounds in this category do. It works upstream, at the level of mitochondrial integrity. This distinction matters for understanding what SS31 might do: it is a mitochondrial protectant, not a NAD booster.

What Remains Unknown

The optimal dose and dosing schedule for humans have not been established. The long-term safety profile in people is unknown. Whether SS31 works in chronic disease (where mitochondrial damage accumulates over years) as well as it does in acute injury models (like heart attack) is untested. The peptide's ability to cross the blood-brain barrier and reach neurons in living humans has not been directly measured.

It is also unclear whether SS31 would work in combination with other treatments, or whether it would interfere with standard medications. These questions require human trials, and they have not yet been answered. Until they are, SS31 remains a research compound with interesting mechanism but unproven clinical utility.

Frequently Asked Questions

Is SS31 the same as Szeto-Schiller 31?

Yes. SS31 is the abbreviation for Szeto-Schiller 31, named after the researchers who developed it. You may see it referred to by either name in scientific literature.

Can I buy SS31 as a supplement?

No. SS31 is not approved for sale as a dietary supplement or drug in the United States. Any product claiming to contain SS31 is not regulated by the FDA and its contents cannot be verified. It is available only through clinical trials or research institutions.

Does SS31 work better than other antioxidants?

SS31 works differently from typical antioxidants—it targets mitochondria specifically rather than neutralizing free radicals throughout the cell. Animal studies suggest this targeted approach may be more effective for mitochondrial dysfunction, but direct human comparisons with other compounds have not been done.

Will SS31 ever be approved as a medicine?

That depends on whether large human trials show it is safe and effective for a specific disease. Several trials are ongoing or have been completed, but results have not yet led to FDA approval. The path from promising animal data to approved medicine typically takes many years and substantial investment.

What is the difference between SS31 and NAD boosters like NMN or NR?

SS31 protects mitochondrial structure and reduces oxidative stress inside mitochondria. NAD boosters like NMN and NR increase the availability of NAD, a coenzyme used in energy production and cellular repair. They work through different mechanisms, though both may support mitochondrial health indirectly.